It looks like RGS management remain doggedly determined to avoid updating shareholders until the last possible moment on the reasons for the second missed timetable for securing a Progenza licensing deal in Japan, and with an outline of 'where to from here'.
The next quarterly report (due around 25 January) would seem to be that last possible moment.
zeno9
